Cognition Therapeutics INC (CGTX) — 10-Q Filings

10-Q Filings (6)

• Cognition Therapeutics Narrows Loss, Boosts Cash with $27.9M Offering — Nov 6, 2025 Risk: high
  Cognition Therapeutics Inc. (CGTX) reported a net loss of $4.93 million for the three months ended September 30, 2025, a significant improvement from the $9.94
• Cognition Therapeutics Fuels R&D with $5.1M Equity Raise — Aug 7, 2025 Risk: high
  COGNITION THERAPEUTICS INC (CGTX) reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage biotechnology status.
• Cognition Therapeutics Q1 2025 Financial Update — May 7, 2025 Risk: medium
  Cognition Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $59,854,877 in Additional Paid-In Capital for the first q
• Cognition Therapeutics Q3 2024 Update — Nov 13, 2024 Risk: medium
  Cognition Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $32,165,478 and total liabilities of $
• Cognition Therapeutics Q2 2024 10-Q Filed — Aug 8, 2024 Risk: medium
  Cognition Therapeutics Inc. filed a 10-Q for the period ending June 30, 2024. The company reported total assets of $32,165,478 and total liabilities of $40,112,
• Cognition Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: low
  COGNITION THERAPEUTICS INC (CGTX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Cognition Therapeutics Inc. filed a 10-Q report for the period en

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX